Table 1 Baseline characteristics of all randomized patients
Group C (ribavirin 800 mg) | Group D (ribavirin 400 mg) | All patients | |
|---|---|---|---|
n | 31 | 51 | 82 |
Age, years ± SD | 36.6 ± 11.0 | 34.9 ± 9.9 | 35.5 ± 10.3 |
Sex, male/female | 13/18 | 21/30 | 34/48 |
Mean baseline HCV RNA (Mio. IU/mL) ± SD | 1.447 ± 2.93 | 0.869 ± 1.46 | 1.083 ± 2.13 |
Mean Body weight (kg) ± SD | 74.2 ± 18.8 | 68.7 ± 13.9 | 70.8 ± 16.0 |
Mean BMI ± SD | 24.5 ± 5.7 | 23.3 ± 3.6 | |
Means by which HCV was acquired, n (%) | |||
Blood transfusion | 3 (9.7) | 6 (11.8) | 9 (11) |
Intravenous drug use | 20 (64.5) | 28 (54.9) | 48 (58.5) |
Other | 3 (9.7) | 2 (3.9) | 5 (6.1) |
Unknown | 5 (16.1) | 15 (29.4) | 20 (24.4) |